Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today highlighted data from research and clinical-stage programs presented over the past week at ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Sangamo BioSciences (SGMO) PT Raised to $6 at WedbushMay 16, 2017 8:45 AM Sangamo Therapeutics Presents Recent Developments from Research and Clinical Programs at Annual Meeting of the American Society of Gene & Cell TherapyMay 15, 2017 8:01 AM